About GlaxoSmithKline plc (NYSE:GSK)
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Major
- Sub-Industry: N/A
- Symbol: NYSE:GSK
- CUSIP: N/A
- Web: www.gsk.com
Capitalization:- Market Cap: $105.78 billion
- Outstanding Shares: 2,443,000,000
Average Prices:- 50 Day Moving Avg: $41.82
- 200 Day Moving Avg: $40.23
- 52 Week Range: $37.20 - $45.58
P/E:- Trailing P/E Ratio: 49.43
- Foreward P/E Ratio: 15.14
- P/E Growth: 1.18
Sales & Book Value:- Annual Revenue: $37.31 billion
- Price / Sales: 2.84
- Book Value: $0.90 per share
- Price / Book: 48.11
Dividend:- Annual Dividend: $1.83
- Dividend Yield: 4.5%
Profitability:- EBIDTA: $9.37 billion
- Net Margins: 3.11%
- Return on Equity: 100.68%
- Return on Assets: 8.68%
Debt:- Debt-to-Equity Ratio: 2.95%
- Current Ratio: 0.88%
- Quick Ratio: 0.61%
Misc:- Average Volume: 2.97 million shs.
- Beta: 0.94
- Short Ratio: 2.04
Frequently Asked Questions for GlaxoSmithKline plc (NYSE:GSK)
What is GlaxoSmithKline plc's stock symbol?
GlaxoSmithKline plc trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."
How often does GlaxoSmithKline plc pay dividends? What is the dividend yield for GlaxoSmithKline plc?
GlaxoSmithKline plc announced a quarterly dividend on Wednesday, April 26th. Investors of record on Friday, May 12th will be paid a dividend of $0.483 per share on Thursday, July 13th. This represents a $1.93 dividend on an annualized basis and a yield of 4.46%. The ex-dividend date of this dividend is Wednesday, May 10th. This is a positive change from GlaxoSmithKline plc's previous quarterly dividend of $0.46. View GlaxoSmithKline plc's Dividend History.
How were GlaxoSmithKline plc's earnings last quarter?
GlaxoSmithKline plc (NYSE:GSK) issued its earnings results on Wednesday, April, 26th. The company reported $0.62 EPS for the quarter, hitting the Thomson Reuters' consensus estimate of $0.62. The firm earned $9.23 billion during the quarter, compared to the consensus estimate of $9.09 billion. GlaxoSmithKline plc had a return on equity of 100.68% and a net margin of 3.11%. View GlaxoSmithKline plc's Earnings History.
Where is GlaxoSmithKline plc's stock going? Where will GlaxoSmithKline plc's stock price be in 2017?
18 brokers have issued 12 month price targets for GlaxoSmithKline plc's shares. Their forecasts range from $37.00 to $50.00. On average, they anticipate GlaxoSmithKline plc's share price to reach $45.67 in the next year. View Analyst Ratings for GlaxoSmithKline plc.
Who are some of GlaxoSmithKline plc's key competitors?
Some companies that are related to GlaxoSmithKline plc include Novartis AG (NVS), Pfizer (PFE), Merck & Co. (MRK), Sanofi SA (SNY), AbbVie (ABBV), Bristol-Myers Squibb Co (BMY), AstraZeneca plc (AZN), Eli Lilly and Co (LLY), Shire PLC (SHPG), GW Pharmaceuticals PLC- (GWPH), Aerie Pharmaceuticals (AERI), Impax Laboratories (IPXL), TherapeuticsMD (TXMD), Retrophin (RTRX), Assembly Biosciences (ASMB), Rockwell Medical (RMTI), Zogenix (ZGNX) and Alimera Sciences (ALIM).
Who owns GlaxoSmithKline plc stock?
GlaxoSmithKline plc's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (0.97%), Fisher Asset Management LLC (0.49%), State Street Corp (0.43%), Hotchkis & Wiley Capital Management LLC (0.31%), Bank of America Corp DE (0.28%) and Bank of New York Mellon Corp (0.24%). View Institutional Ownership Trends for GlaxoSmithKline plc.
Who sold GlaxoSmithKline plc stock? Who is selling GlaxoSmithKline plc stock?
GlaxoSmithKline plc's stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Hotchkis & Wiley Capital Management LLC, Ameriprise Financial Inc., State Street Corp, Credit Suisse AG, Bank of New York Mellon Corp, BB&T Securities LLC and Jarislowsky Fraser Ltd. View Insider Buying and Selling for GlaxoSmithKline plc.
Who bought GlaxoSmithKline plc stock? Who is buying GlaxoSmithKline plc stock?
GlaxoSmithKline plc's stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Thrivent Financial For Lutherans, Renaissance Technologies LLC, Bank of America Corp DE, Global Financial Private Capital LLC, Equity Investment Corp Acquisition Inc, MARSHALL WACE ASIA Ltd and Marshall Wace North America L.P.. View Insider Buying and Selling for GlaxoSmithKline plc.
How do I buy GlaxoSmithKline plc stock?
Shares of GlaxoSmithKline plc can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of GlaxoSmithKline plc stock cost?
One share of GlaxoSmithKline plc stock can currently be purchased for approximately $43.30.
Earnings History for GlaxoSmithKline plc (NYSE:GSK)Earnings History by Quarter for GlaxoSmithKline plc (NYSE:GSK)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 4/26/2017 | 3/31/2017 | $0.62 | $0.62 | $9.09 billion | $9.23 billion | View | N/A |  |
| 2/8/2017 | 12/31/2016 | $0.57 | $0.65 | $9.21 billion | $9.43 billion | View | Listen | |
| 10/26/2016 | Q316 | $0.77 | $0.83 | $8.92 billion | $9.90 billion | View | Listen | |
| 10/28/2015 | Q3 | $0.60 | $0.71 | $6.07 billion | $6.13 billion | View | N/A | |
| 7/29/2015 | Q215 | $0.50 | $0.53 | $9.14 billion | $9.02 billion | View | N/A | |
| 5/6/2015 | Q115 | $0.55 | $0.48 | $8.55 billion | $8.51 billion | View | N/A | |
| 2/4/2015 | Q414 | $0.86 | $0.82 | $6.14 billion | $6.19 billion | View | N/A | |
| 10/22/2014 | Q314 | $0.79 | $0.90 | $9.76 billion | $9.12 billion | View | Listen | |
| 7/23/2014 | Q114 | $0.71 | $0.65 | $10.13 billion | $9.47 billion | View | N/A | |
| 4/30/2014 | Q413 | $0.72 | $0.70 | $10.36 billion | $9.44 billion | View | N/A | |
| 2/5/2014 | Q4 | $0.30 | $0.30 | $6.84 billion | $6.91 billion | View | N/A | |
| 10/23/2013 | Q313 | | $0.31 | $10.31 billion | $10.09 billion | View | N/A | |
| 7/24/2013 | | $0.26 | $0.26 | | $6.62 billion | View | N/A | |
| 4/25/2012 | | $0.29 | $0.27 | | | View | N/A | |
| 2/7/2012 | | $0.30 | $0.28 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for GlaxoSmithKline plc (NYSE:GSK)2017 EPS Consensus Estimate: $2.89
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | $0.59 | $0.63 | $0.61 |
| Q2 2017 | 1 | $0.71 | $0.71 | $0.71 |
| Q3 2017 | 1 | $0.83 | $0.83 | $0.83 |
| Q4 2017 | 1 | $0.74 | $0.74 | $0.74 |
(Data provided by Zacks Investment Research)
Current Dividend Information for GlaxoSmithKline plc (NYSE:GSK)| Next Dividend: | 7/13/2017 |
| Annual Dividend: | $1.83 |
| Dividend Yield: | 4.23% |
| Dividend Growth: | -3.10% (3 Year Average) |
| Payout Ratio: | 389.36% (Trailing 12 Months of Earnings)
64.89% (Based on This Year's Estimates)
63.99% (Based on Next Year's Estimates)
|
Dividend History by Quarter for GlaxoSmithKline plc (NYSE:GSK)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 4/26/2017 | quarterly | $0.48 | 4.79% | 5/10/2017 | 5/12/2017 | 7/13/2017 |
| 2/8/2017 | quarterly | $0.57 | 5.76% | 2/22/2017 | 2/24/2017 | 4/13/2017 |
| 10/26/2016 | | $0.46 | | 11/2/2016 | 11/4/2016 | 1/12/2017 |
| 7/27/2016 | | $0.49 | | 8/10/2016 | 8/12/2016 | 10/13/2016 |
| 4/28/2016 | | $0.55 | | 5/11/2016 | 5/13/2016 | 7/14/2016 |
| 10/28/2015 | | $0.58 | | 11/10/2015 | 11/13/2015 | 1/14/2016 |
| 5/7/2015 | quarterly | $0.58 | 5.22% | 5/13/2015 | 5/15/2015 | 7/9/2015 |
| 2/5/2015 | quarterly | $0.70 | 6.05% | 2/18/2015 | 2/20/2015 | 4/9/2015 |
| 10/23/2014 | quarterly | $0.61 | 5.41% | 11/5/2014 | 11/7/2014 | 1/8/2015 |
| 7/24/2014 | quarterly | $0.65 | 5.18% | 8/6/2014 | 8/8/2014 | 10/2/2014 |
| 5/1/2014 | quarterly | $0.64 | 4.62% | 5/14/2014 | 5/16/2014 | 7/10/2014 |
| 2/5/2014 | | $0.75 | | 2/19/2014 | 2/21/2014 | 4/10/2014 |
| 2/6/2014 | quarterly | $0.75 | 5.73% | 2/19/2014 | 2/21/2014 | 4/10/2014 |
| 10/24/2013 | quarterly | $0.62 | 4.76% | 11/13/2013 | 11/15/2013 | 1/9/2014 |
| 7/25/2013 | quarterly | $0.55 | 4.27% | 8/7/2013 | 8/9/2013 | 10/3/2013 |
| 4/25/2013 | quarterly | $0.55 | 4.25% | 5/8/2013 | 5/10/2013 | 7/11/2013 |
| 2/7/2013 | quarterly | $0.07 | 0.61% | 2/20/2013 | 2/22/2013 | 4/11/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for GlaxoSmithKline plc (NYSE:GSK)Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 8.41%
Insider Trades by Quarter for GlaxoSmithKline plc (NYSE:GSK)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 10/24/2016 | Plc Glaxosmithkline | Major Shareholder | Buy | 66,500 | $14.00 | $931,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for GlaxoSmithKline plc (NYSE:GSK)
Latest Headlines for GlaxoSmithKline plc (NYSE:GSK)
| Source: |
|
| Date | Headline |
|---|
 | Hikma trims FY revenue forecast on Advair U.S. launch delay
www.reuters.com - May 19 at 9:56 AM |
 | Hikma cuts revenue forecast on generic Advair delay; shares sink
www.nasdaq.com - May 19 at 9:56 AM |
 | U.K. stocks break 2-day losing streak after pound’s mini ‘flash crash’
www.marketwatch.com - May 19 at 9:56 AM |
 | Citi Prefers These 4 Stocks Over Pfizer On Bottom-Line Concerns
finance.yahoo.com - May 16 at 5:28 PM |
 | West-Ward Columbus sales to take a hit with FDA delay of its generic Advair
www.bizjournals.com - May 15 at 5:06 PM |
| Francis Chou Buys Endo International PLC, Teva Pharmaceutical Industries, Valeant ...
www.nasdaq.com - May 13 at 9:43 AM |
| Glaxit: GlaxoSmithKline Sees a Top Investor Dump Stock out of 'Frustration'
finance.yahoo.com - May 12 at 6:13 PM |
| Top-10 Glaxo investor Woodford sells out, criticises board
finance.yahoo.com - May 12 at 6:13 PM |
 | Why Big Pharma Is Not at Fault for Record Drug Spending
247wallst.com - May 11 at 6:07 PM |
| Mylan disagrees with FDA over generic Advair delay
www.nasdaq.com - May 10 at 5:41 PM |
| Glaxo reports positive trial of lung treatment
www.marketwatch.com - May 10 at 5:41 PM |
| GlaxoSmithKline Plc : GSK-US: Dividend Analysis : May 12th, 2017 (record date) : By the numbers : May 10, 2017
finance.yahoo.com - May 10 at 5:40 PM |
| Mylan says disagrees with FDA over generic Advair delay
finance.yahoo.com - May 10 at 12:02 PM |
 | GlaxoSmithKline plc (GSK) Given Daily News Impact Rating of 0.16
www.americanbankingnews.com - May 6 at 12:53 AM |
 | 3 powerful reasons to desire GlaxoSmithKline plc right now
www.fool.co.uk - May 5 at 4:07 PM |
 | GSK And Innoviva Announce Positive Results From SLS In Asthma
www.rttnews.com - May 5 at 4:07 PM |
| GlaxoSmithKline plc (GSK) Receiving Somewhat Positive Media Coverage, Study Shows
www.americanbankingnews.com - May 2 at 8:42 PM |
| GSK Makes Bullish Cross Above Critical Moving Average
www.nasdaq.com - May 2 at 5:42 PM |
| Analyzing GlaxoSmithKline’s Global Pharmaceutical Performance
finance.yahoo.com - May 2 at 5:42 PM |
| How GlaxoSmithKline’s Consumer Healthcare Segment Fared in 1Q17
finance.yahoo.com - May 2 at 5:42 PM |
| ETFs with exposure to GlaxoSmithKline Plc : May 1, 2017
finance.yahoo.com - May 1 at 5:16 PM |
| GlaxoSmithKline announces $139 million investment in Rockville
www.bizjournals.com - May 1 at 12:50 PM |
| Is This Big Pharma Stock's Sky-High Dividend Yield Sustainable?
finance.yahoo.com - May 1 at 12:50 PM |
| How Did GlaxoSmithKline’s HIV Business Perform in 1Q17?
finance.yahoo.com - May 1 at 12:50 PM |
| Triad college awarded $25,000 STEM grant
finance.yahoo.com - May 1 at 12:50 PM |
| GlaxoSmithKline making $139M investment in Rockville plant
finance.yahoo.com - May 1 at 12:50 PM |
| Glaxo (GSK) Reports In-Line Q1 Earnings, Reiterates View - Yahoo Finance
finance.yahoo.com - April 29 at 6:07 PM |
| GlaxoSmithKline plc (GSK) Given Media Impact Score of 0.23
www.americanbankingnews.com - April 29 at 1:43 PM |
| GlaxoSmithKline plc (GSK) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 28 at 10:52 PM |
| GlaxoSmithKline’s 1Q17 Earnings Surpass Analysts’ Estimates
finance.yahoo.com - April 28 at 8:33 PM |
| GlaxoSmithKline Plc :GSK-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28, 2017
finance.yahoo.com - April 28 at 3:32 PM |
| GlaxoSmithKline plc (GSK) Issues Quarterly Earnings Results, Meets Expectations
www.americanbankingnews.com - April 27 at 6:02 PM |
| GlaxoSmithKline plc (gsk) Plans Dividend of $0.48
www.americanbankingnews.com - April 27 at 2:17 PM |
| GlaxoSmithKline plc (GSK) Earning Favorable News Coverage, Report Finds
www.americanbankingnews.com - April 26 at 9:26 PM |
| GlaxoSmithKline Beats Q1 Estimates, Keeps Full Year Targets In Place
finance.yahoo.com - April 26 at 7:49 PM |
| GlaxoSmithKline’s 1Q17 Estimates: Consumer Healthcare
finance.yahoo.com - April 26 at 7:49 PM |
| Analyst Ratings and Recommendations for GlaxoSmithKline
finance.yahoo.com - April 26 at 7:49 PM |
| New Glaxo Boss Emma Walmsley Seeks Sharper R&D Edge
finance.yahoo.com - April 26 at 7:49 PM |
 | Glaxo meets 1Q profit forecasts
marketbeat.com - April 26 at 10:28 AM |
| [$$] GlaxoSmithKline 1Q Results Expected to Get Boost From Weak Pound
finance.yahoo.com - April 25 at 5:06 PM |
| GlaxoSmithKline plc (GSK) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 25 at 3:42 PM |
| GlaxoSmithKline plc's (GSK) Neutral Rating Reaffirmed at JPMorgan Chase & Co.
www.americanbankingnews.com - April 25 at 2:35 PM |
| This fast-growing pharmaceutical stock blows GlaxoSmithKline plc out of the water
www.fool.co.uk - April 24 at 5:18 PM |
| FY2017 EPS Estimates for GlaxoSmithKline plc Lowered by Jefferies Group (GSK)
www.americanbankingnews.com - April 24 at 9:12 AM |
| Leerink Swann Analysts Decrease Earnings Estimates for GlaxoSmithKline plc (GSK)
www.americanbankingnews.com - April 24 at 8:04 AM |
| GlaxoSmithKline plc (GSK) Earning Favorable Press Coverage, Analysis Finds
www.americanbankingnews.com - April 23 at 6:15 PM |
| What's in Store for GlaxoSmithKline (GSK) in Q1 Earnings?
finance.yahoo.com - April 21 at 5:31 PM |
| Analyst Estimates for Novartis’s 1Q17 Earnings
finance.yahoo.com - April 21 at 5:31 PM |
| Barclays -- Mired In Mud (Again) -- Should Dump Its CEO
finance.yahoo.com - April 21 at 5:31 PM |
 | What's in Store for GlaxoSmithKline (GSK) in Q1 Earnings?
www.zacks.com - April 21 at 11:15 AM |
GlaxoSmithKline plc (GSK) Chart for Monday, May, 22, 2017
